INmune Bio (INMB) IPO Opens at $8.44
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “INMB”
February 4, 2019 8:55 AM ESTLA JOLLA, CA, Feb. 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (INmune or the Company), an immunotherapy company focused on developing therapies that harness the patients innate immune system to fight disease, today announced that the Companys common stock is expected to commence trading on The Nasdaq Capital Market, on Monday, February 4, 2019 under the ticker symbol INMB.
On February 1, 2019, INmune closed its initial public offering (IPO) of 1,020,560 shares of its common stock at of $8.00 per share for a total of $8,166,560 in gross proceeds before placement agent fees and offering expenses.
Univest Securities, LLC... More
INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol “INMB”
February 4, 2019 8:55 AM ESTLA JOLLA, CA, Feb. 04, 2019 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (INmune or the Company), an immunotherapy company focused on developing therapies that harness the patients innate immune system to fight disease, today announced that the Companys common stock is expected to commence trading on The Nasdaq Capital Market, on Monday, February 4, 2019 under the ticker symbol INMB.
On February 1, 2019, INmune closed its initial public offering (IPO) of 1,020,560 shares of its common stock at of $8.00 per share for a total of $8,166,560 in gross proceeds before placement agent fees and offering expenses.
Univest... More
